Photo taken from Enes Erul/X
May 9, 2024, 00:21
Enes Erul: Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors
Enes Erul, Oncology Fellow at Ankara Üniversitesi, shared on X:
“Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types.”
Source: Enes Erul/X